Jeito Capital, a leading biotechnology investor, has successfully closed a €1 billion ($1.2 billion) fund, marking the largest raise for a fully independent European biopharma fund. The Jeito II Fund aims to invest in 15 to 20 early-stage drugmakers across Europe, with each receiving up to €150 million. Jeito, which previously raised €534 million in 2021, intends to support companies focused on significant therapeutic areas like obesity, oncology, and autoimmune conditions. Despite a general decline in venture funding for biotech in early 2026, Jeito’s strong fundraising reflects growing confidence in the European biopharma sector’s innovation potential.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/jeito-capital-biopharma-venture-fund-billion/816946/
